Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00361231
Status:
COMPLETED
Last Update Posted:
2017-02-07
First Post:
2006-08-04
Brief Title:
Gemcitabine Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Organization Data
Organization:
Massachusetts General Hospital
Class:
OTHER
Study ID:
05-349
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Massachusetts General Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Andrew X Zhu MD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Massachusetts General Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Dana-Farber Cancer Institute | OTHER |
| Genentech Inc | INDUSTRY |
| Sanofi | INDUSTRY |
| Beth Israel Deaconess Medical Center | OTHER |
| Brigham and Womens Hospital | OTHER |